Zhifei’s Semaglutide Injection Gets NMPA Filing Acceptance for Type 2 Diabetes

This filing acceptance signals progress in China's biosimilar race for a high-demand GLP-1 therapy, but the focus here is regulatory process, not commercial outcome. For Zhifei, it extends pipeline depth beyond vaccines, though approval and market entry remain distant. The significance lies in competitive positioning against other domestic semaglutide developers, as NMPA's review timeline and eventual pricing dynamics will shape adoption. Whether this moves faster than rivals and how regulators weigh biosimilar interchangeability are the key watchpoints.